<DOC>
	<DOCNO>NCT00017082</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness oxaliplatin treat patient recurrent metastatic colorectal cancer .</brief_summary>
	<brief_title>Oxaliplatin Treating Patients With Recurrent Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine overall response rate , onset duration partial complete response , duration stable disease patient recurrent metastatic colorectal cancer treat oxaliplatin . II . Determine overall survival patient treated drug . III . Determine proportion patient tumor-related symptomatic improvement time tumor-related symptomatic worsening patient treat drug . IV . Determine time disease progression patient treat drug . V. Determine proportion patient achieve stable disease treat drug . VI . Determine safety drug patient population . OUTLINE : This multicenter study . Patients receive oxaliplatin IV 120 minute day 1 . Courses repeat every 3 week 1 year absence disease progression . Patients follow 30 day every 8 week 10 month . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm recurrent metastatic adenocarcinoma colon rectum Not amenable potentially curative treatment ( e.g. , inoperable metastatic disease ) Must receive 2 , 2 , prior chemotherapy regimens metastatic recurrent disease , include follow : Firstline therapy bolus continuous infusion fluorouracil ( 5FU ) ( without leucovorin calcium ) capecitabine OR Adjuvant therapy 5FU leucovorin calcium relapse within 6 month completion firstline therapy Secondline therapy irinotecan adjuvant 5FU leucovorin calcium treatment failure Progressive disease CT scan MRI firstline treatment OR within 6 month completion adjuvant chemotherapy AND secondline irinotecan adjuvant treatment failure At least 1 unidimensionally measurable lesion At least 20 mm CT scan MRI At least 10 mm spiral CT scan PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN ( 6 time ULN liver metastasis present ) Alkaline phosphatase great 2 time ULN ( 6 time ULN liver metastasis present ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No unstable angina No myocardial infarction within past 6 month No New York Heart Association class III IV symptomatic congestive heart failure No serious cardiac arrhythmia Pulmonary : No interstitial pneumonia extensive symptomatic fibrosis lung Other : No history intolerance antiemetic ( e.g. , 5HT3 antagonist ) antidiarrheal medication ( e.g. , loperamide ) administer concurrently study chemotherapy No history allergy drug contain platinum No know concurrent peripheral neuropathy No diabetes No active infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study No active cancer another primary site except surgically treat nonmelanoma skin cancer , carcinoma situ cervix , localized prostate cancer undetectable PSA level PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy , include irinotecan , metastatic recurrent disease recover No prior firstline chemotherapy agent metastatic recurrent disease No prior adjuvant irinotecan No prior oxaliplatin Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy No prior radiotherapy target lesion unless documented disease progression within radiation portal Surgery : See Disease Characteristics More 4 week since prior surgery primary metastatic disease recover Other : No prior investigational anticancer drug administer irinotecan No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>